Table 2. Clinical characteristics of 101 gastric cancer patients with and without RASSF1A and PCDH10 methylation in plasma DNA.
| Clinical variables | RASSF1A | p-value | PCDH10 | p-value | ||
|---|---|---|---|---|---|---|
| Methylated (n = 84) | Non-methylated (n = 17) | Methylated (n = 95) | Non-methylated (n = 6) | |||
| Gender | 0.99 | 0.69 | ||||
| Female | 37 (44.05%) | 7 (41.18%) | 42 (44.21%) | 2 (33.33%) | ||
| Male | 47 (55.95%) | 10 (58.82%) | 53 (55.79%) | 4 (66.67%) | ||
| Age (years) | 1.00 | 0.69 | ||||
| <50 | 35 (41.67%) | 7 (41.18%) | 39 (68.42%) | 3 (50.00%) | ||
| >50 | 49 (58.33%) | 10 (58.82%) | 56 (31.58%) | 3 (50.00%) | ||
| Region of cancer | 0.34 | 1.00 | ||||
| Upper site and Body | 19 (22.62%) | 6 (35.29%) | 24 (25.26%) | 1 (16.67%) | ||
| Lower site | 41 (48.81%) | 7 (41.18%) | 45 (47.37%) | 3 (50.00%) | ||
| Not specific | 24 (28.57%) | 4 (23.53%) | 26 (27.37%) | 2 (33.33%) | ||
| Histopathology (Adenocarcinoma) | 1.00 | 1.00 | ||||
| NOS | 58 (69.05%) | 12 (70.59%) | 66 (69.47%) | 4 (66.67%) | ||
| Intestinal and diffuse type | 26 (30.95%) | 5 (29.41%) | 29 (30.53%) | 2 (33.33%) | ||
| Histology grading (Goseki classification) | 0.001*** | 0.017** | ||||
| Not specific | 14 (16.67%) | 7 (41.18%) | 17 (17.89%) | 4 (66.67%) | ||
| Group I–IV | 70 (83.33%) | 10 (58.82%) | 78 (82.11%) | 2 (33.33%) | ||
| Stage grouping (TNM classification) | 0.002** | 0.023** | ||||
| Not specific | 13 (15.48%) | 10 (64.71%) | 20 (21.05%) | 3 (50.00%) | ||
| I–III | 17 (20.24%) | 6 (29.41%) | 20 (22.11%) | 3 (50.00%) | ||
| IV | 54 (64.29%) | 1 (5.88%) | 55 (56.84%) | 0 (0%) | ||
| Metastasis | 0.005*** | 0.002*** | ||||
| No | 27 (39.29%) | 12 (11.76%) | 33 (34.74%) | 6 (100.0%) | ||
| Yes | 57 (60.71%) | 5 (88.24%) | 62 (65.26%) | 0 (0%) | ||
Notes.
***
p < 0.001.
**
0.001 < p < 0.01.